Cady Berkel Ph.D.
Cady Berkel, Ph.D, splits her time between Arizona State University and Phoenix Children’s Hospital.
Her research focuses on the implementation of evidence-based programs (EBPs) to reduce disparities in multiple domains, including substance use, mental health, sexual risk, and obesity. Based on findings that home practice of program skills is a critical feature of EBPs, she plans to develop an SBIR/STTR proposal for an mHealth system that can be marketed to program developers to support home practice across EBPs to promote effectiveness and scalability.
Sarah Ferraro Cunningham, Psy.D.
Sarah Ferraro Cunningham, Psy.D., is the Co-Founder and Chief Executive Officer of Panaptic, the leader in comprehensive marijuana prevention. She also serves as a psychologist and Regional Linkage Champion at Kaiser Permanente.
As a licensed psychologist and research clinician, Dr. Ferraro Cunningham’s deep concern regarding the harmful impact of marijuana use led her to co-found Panaptic, Inc. Panaptic relates scientific knowledge to those who most need accurate information about marijuana use – young people, families and schools. They have created dynamic e-learning courses tailored to the interests and learning needs of high school students, parents and educators. Dr. Ferraro Cunningham’s goal is to optimize Panaptic’s business model in order to transform the culture of marijuana and drug use nationwide.
Jennifer Dahne, Ph.D.
Jennifer Dahne, Ph.D. is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences, Addiction Sciences Division at the Medical University of South Carolina and Chief Executive Officer of Behavioral Activation Tech, LLC.
Dr. Dahne’s research focuses on the development of novel interventions simultaneously targeting mental health and addiction, delivering these interventions in the real world (e.g., primary care), and utilizing technology to overcome treatment barriers.
Sycarah D. Fisher, Ph.D. NCSP
Sycarah D. Fisher, Ph.D., is currently an Assistant Professor in the School Psychology Program at the University of Kentucky.
Dr. Fisher’s goal is to develop a technological web-based system for identifying and tracking the needs and services of our most vulnerable youth. This system would allow vested community organizations to have access to identified youth with substance use problems as well as their past and present levels of care. The implementation of a shared web-based platform will reduce treatment costs by preventing duplicative services while creating a technological solution to the provision of a continuum of care and wrap-around services.
Amanda K. Gilmore, Ph.D.
Amanda K. Gilmore, Ph.D., is an Assistant Professor (Research) at the College of Nursing and Department of Psychiatry & Behavioral Sciences at the Medical University of South Carolina.
Dr. Gilmore’s research uses innovative technology to reduce substance use, sexual assault, and sexual risk behaviors among high-risk groups. She is interested in learning more about how to bring a behaviorally-focused mHealth application to the market. She is currently leading two NIH-funded projects. The first is her NIDA-funded career development award to develop a tablet-based, integrated intervention for adolescents during their pediatric wellness appointments. Her second project is an NIAAA-funded grant to plan for a clinical trial to test the efficacy of an mHealth intervention for alcohol use and sexual assault among college campuses.
Bryan W. Heckman, Ph.D.
Bryan W. Heckman, Ph.D. is currently an Assistant Professor at the Medical University of South Carolina and Associate Research Member at the Hollings Cancer Center.
Dr. Heckman founded a digital healthcare company called b2: Population Health Solutions. His team produced a smartphone application that uses context sensing and machine learning to automate treatment. The algorithm that they developed detects smoking relapse risk and delivers just-in-time relapse prevention interventions. His consumer-driven approach aims to facilitate user engagement by delivering a positive user experience and reducing treatment burden.
Andrew S. Huhn, Ph.D.
Andrew S. Huhn, Ph.D., is currently a Postdoctoral Research Fellow in the Behavioral Pharmacology Research Unit at Johns Hopkins School of Medicine and has been a Co-Investigator on two Phase 3 multi-site trials at Alkermes.
Dr. Huhn is interested in combining his scientific skillset as a clinical researcher in neuroscience with the business acumen necessary to effect change in Opioid Use Disorder treatment. His goal is to tailor scientific research that influences public policy, healthcare systems, and insurance companies in adopting treatment options that are smart, cohesive, and cost-effective. His first idea is to develop a software program that utilizes neuroimaging and other factors to predict relapse risk and guide the course of treatment. His second idea is to directly address the lack of continuity between OUD providers in establishing a seamless continuum of care.
Aaron Lazarus and Omeed Anthony Rahimi
Aaron Lazarus is the Co-Founder and Chief Executive Officer of EncepHeal Therapeutics Inc., and Omeed Rahimi, Ph.D., is the Co-Founder and Chief Science Officer of EncepHeal Therapeutics Inc.
There is a need to develop a therapeutic for psychostimulants that can attenuate craving while displaying little to no abuse liability, and Mr. Lazarus’s and Dr. Rahimi’s company, EncepHeal Therapeutics Inc., looks to solve this problem with an exclusive license of newly patented modafinil analogs from the National Institute on Drug Abuse. Their goal is to bridge the drug development gap by propelling these innovative biomedical discoveries into next-generation neurotherapeutics.
Angela E. Lee-Winn, Ph.D.
Angela E. Lee-Winn, Ph.D., is a psychiatric epidemiologist and currently a postdoctoral fellow in the NIDA Drug Dependence Epidemiology Training Program at Johns Hopkins Bloomberg School of Public Health.
Dr. Lee-Winn’s main research interests are 1) assessment of psychosocial correlates of mental disorders at a population level and 2) the use of mindfulness strategies for prevention of mental disorders. Her long-term goal is to develop and test a mindfulness program for promoting self-regulation, a common risk factor of various mental health problems, including substance use. She plans to create a personalized app by adapting evidence-based mindfulness programs that are most relevant to substance use (e.g. Mindfulness-based Relapse Prevention) to suit the particular needs of at-risk individuals.
Linda Maguire, PhDc, MHS, MA, BMus, ABA
Linda Maguire is CEO and CSO of Maguire Brain Health Sciences, LLC. Linda recently completed her Ph.D. (abd) in Health and Strategic Risk Communication at George Mason University (GMU). A professionally-trained opera singer (Oberlin Conservatory, Univ of Toronto) turned neuroscientist and bio-psychologist (GMU, Johns Hopkins Bloomberg School of Public Health), she lecture-demonstrates on the many powers of precision music programming to escort mood, cognition, function and behavior (via physiologic mediation) in both patients and healthy clients.
Throughout the course of her studies, she has developed an array of working, validated aging brain health innovations and products. A Johns Hopkins’ trained mental health scientist (MHS), gerontologist (certification) and world renown vocal musician-performer, her “Prescription iPods” represent a Johns Hopkins’ awarded intervention (“Best Practice” award) for those with dementias, autism, depression, insomnia, PTSD, schizophrenia and other neuropathologies, as well as for healthy infant, child and adult brain development. Linda holds music degrees from the Oberlin Conservatory of Music and the University of Toronto, gerontology and mental health science degrees from Johns Hopkins Bloomberg School of Public Health, a Bio-psychology (MA, Cognitive and Behavioral Neuroscience), Applied Behavioral Analysis (Certificate) and Health and Risk Communication degrees (Ph.D. abd) from George Mason University. She is a professional musician, neuroscientist, aging brain health specialist and innovator. (Please visit www.MaguireHealth.com ). Her product, the Brain-d’AidTM is a focal cooling triage that attenuates subcranial inflammation after concussion. The Brain-d’AidTM product also provides impact analysis as well as individualized, structured recovery schedule and scientifically-validated strategies contingent on specific brain areas of concussive injury and tissue damage. The Brain-d’AidTM cools focal area of concussive hit, then escorts pursuant weeks of recovery via app-scheduled reminders, soothing music playlists, and strategic brain recovery exercises. The Brain-d’AidTM is cost-effective while the product’s communication campaign is well-drafted and set to move to full implementation and dissemination, which Ms. Maguire hopes to further and achieve through the Yale SOM ‘Innovation to Impact’ program. For the Prescription iPod clinical interface, Ms Maguire seeks funding in 2019 from the 100&Change MacArthur Foundation.
Vera Nezgovorova, M.D.
Dr. Vera Nezgovorova graduated from Saint-Petersburg State University Russia in 2009, where she defended a diploma thesis in psychiatry. She then completed her residency in adult neurology, followed by a scientific fellowship under European Federation of Neurological Societies umbrella at Pitie-Salpetriere hospital at Paris, France. She has been a postdoctoral associate at Yale University in 2014-2017. Dr. Nezgovorova is currently a clinical research fellow in the Autism, Obsessive Compulsive Disorder spectrum, Anxiety and Depression program at Montefiore Medical Center at Albert Einstein College of Medicine.
Steven L. Proctor, Ph.D.
Steven L. Proctor, Ph.D., is a Senior Research Professor at Albizu University, where he directs the Institutional Center for Scientific Research at the Miami campus. He also serves as the Principal at PRO Health Group, and Chief Research Officer at AiR Healthcare Solutions.
Dr. Proctor’s product, “Protracted Recovery Outcomes Monitoring, Assessment, & Referral for Families,” is a novel, long-term telehealth intervention involving routine contacts with both patients and their families to assess various addiction and mental health vital signs, as well as provide support, referrals as indicated, and accountability as patients transition from the “safe” structured confines of acute care to their home environment for the continuing care phase of recovery (i.e., the “real world”).
Sarah E. Snider, Ph.D.
Sarah E. Snider, Ph.D., is the Chief Executive Officer and Co-Founder of BEAM Diagnostics, Inc., as well as a Post-Doctoral Associate at the Addiction Recovery Research Center at Virginia Tech Carilion Research Institute.
BEAM Diagnostics, Inc. is a company founded on the concept that reinforcer pathology undergirds self-control failure in an expansive range of health and financial behaviors. Reinforcer pathology is a theoretical model of maladaptive health behaviors that proposes prepotent influences of two decision making processes, (1) Delay Discounting and (2) Behavioral Economic Demand. Dr. Snider’s initial goal is to develop a commercially-available reinforcer pathology tool to predict alcohol use severity, implemented via web application, which incorporates the decision-making tasks, RPscore algorithm, and user-friendly interface for use by providers.
Ryan D. Stoll
Ryan D. Stoll is currently earning his Ph.D. in Clinical Psychology at Arizona State University under the mentorship of Drs. Armando Pina and Nancy Gonzales. He is the Director of Research Innovation and Dissemination in The Courage Lab at his university, as well as a freelance graphic designer and marketing strategist.
Mr. Stoll helped support Dr. Nancy Gonzales in the re-design of Bridges, which is a group-based prevention program for middle schools designed to help students and their families manage the demands of middle school, prepare for a lifetime of success, and prevent substance use disorders. Unlike existing programs such as Love and Logic, Active Parenting, and Strengthening Families, Bridges uses digital media and collaborative game-based learning approaches to teach youth and families the Bridges skills. Bridges has the capacity to be easily adapted into other formats, including web and mobile, or other settings beyond schools.
Rachel Trobman is the Co-Founder and Chief Executive Officer of Ouchie. Ms. Trobman and her team of technologists and pain management clinicians created Ouchie, a mobile companion for pain management, which is the sole patient engagement application for the U.S. Pain Foundation.
Ouchie uses tracking, cognitive behavioral therapy and community to improve patient engagement and outcomes. Her goal is to integrate with an educational institution to enhance the scientific background for their product, particularly as it relates to resources they provide on the platform. She also believes Ouchie is a valuable preventative tool in combatting opioid abuse and she hopes to do a clinical pilot to build out that hypothesis.
Emily B. Winslow, Ph.D.
Emily B. Winslow, Ph.D., is currently an Assistant Research Professor at the REACH Institute at Arizona State University.
Engagement Solutions is Dr. Winslow’s idea for a training and consultation business that would help directors of social service agencies and health organizations increase participation in their evidence-based parenting interventions by up to 700%. With support from NIDA and NIMH, Winslow developed and evaluated the Parent Engagement Package (PEP), a system of theory-based engagement strategies. Wide dissemination of the PEP has the potential to expand the reach of evidence-based parenting interventions for underserved families whose children are at risk for substance abuse. Dr. Winslow’s ultimate goal is to launch Engagement Solutions.